A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Inclusion Criteria: * Signed informed consent prior to participation in the study. * Active, treatment-naïve choroidal neovascularization (CNV) secondary to AMD. * BCVA ETDRS score between 80 and 25 letters (Snellen equivalent of 20/25 to 20/320), inclusive. * Other protocol-specified inclusion criteria may apply Exclusion Criteria: * CNV secondary to other causes in the Study Eye. * Any history of macular pathology unrelated to AMD but affecting vision or contributing to subretinal or intraretinal fluid. * Any history or evidence of a concurrent intraocular condition in the Study Eye that, in the judgment of the Investigator, could require either medical or surgical intervention during the study to prevent or treat visual loss. * Active ocular or periocular infection or inflammation. * Prior administration of any approved or investigational treatment for neovascular AMD in the Study Eye. * Uncontrolled glaucoma in the Study Eye. * Women who are pregnant or lactating or intending to become pregnant during the study. * Stroke or myocardial infarction in the 6-month period prior to Day 1. * Uncontrolled blood pressure defined as a systolic value \> 180 mmHg or diastolic value ≥100 mmHg while at rest. * History of a medical condition that, in the judgment of the Investigator, would preclude scheduled study visits, completion of the study, or a safe administration of investigational product. * Other protocol-specified exclusion criteria may apply.